Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

WGc0201

Phase 1Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Hepatitis B VirusRecruiting

Chronic Hepatitis B VirusPhase 1

Recruiting

Timeline

Expected Milestones

Q3 2031

Phase 1Recruiting

Chronic Hepatitis B Virus

NCT07051187

Clinical

Trials by Indication[1]

Chronic Hepatitis B Virus1 trial

An Open-Label, Single-Arm, Dose-Escalation Phase I Clinical Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection

Recruiting·JJiyan Liu·Phase 1·NCT07051187·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for WGc0201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — WGc0201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for WGc0201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiyan Liu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJiyan Liu

Related News